PROTECT试验最终总生存分析:肾切除术后辅助帕唑帕尼对比安慰剂
PROTECT是一项随机双盲安慰剂对照3期研究,评估高危局部晚期肾细胞癌根治性肾切除术后辅助帕唑帕尼(600 mg)的疗效,两组各769例。最终总生存分析中位随访约76-77个月,显示帕唑帕尼与安慰剂组总生存无显著差异(HR 1.0,95%CI 0.80-1.26,名义P>0.9),不支持辅助帕唑帕尼用于该人群。
要点
- 局部晚期肾癌肾切除术后辅助帕唑帕尼未改善总生存。
- 帕唑帕尼组与安慰剂组OS无显著差异(HR 1.0,95%CI 0.80-1.26)。
- T4病变者OS更差,BMI≥30 kg/m2者OS更好。
核心结论
- 辅助帕唑帕尼未给局部晚期肾癌肾切除术后高危复发患者带来总生存获益。
研究设计与样本
- 随机、双盲、安慰剂对照3期PROTECT试验(NCT01235962),帕唑帕尼组769例、安慰剂组769例。
主要发现
- 帕唑帕尼与安慰剂组总生存无显著差异(HR 1.0,95%CI 0.80-1.26,名义P>0.9),中位随访帕唑帕尼76个月(IQR 66-84)、安慰剂77个月(IQR 69-85)。
- T4病变患者OS较非T4患者更差。
- BMI≥30 kg/m2患者OS优于BMI较低者。
- 治疗后2年仍无病生存者OS显著优于2年内复发者。
关键数值与推荐
- 主要分析显示帕唑帕尼600 mg与安慰剂在无病生存方面无差异。
临床怎么用
- 不推荐帕唑帕尼作为局部晚期肾癌肾切除术后的辅助治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most studies indicate no benefit of adjuvant therapy with VEGFR tyrosine kinase inhibitors in advanced renal cell carcinoma (RCC). PROTECT (NCT01235962) was a randomized, double-blind, placebo-controlled phase 3 study to evaluate adjuvant pazopanib in patients with locally advanced RCC at high risk of relapse after nephrectomy (pazopanib, n = 769; placebo, n = 769). The results of the primary analysis showed no difference in disease-free survival between pazopanib 600 mg and placebo. Here we report the final overall survival (OS) analysis (median follow-up: pazopanib, 76 mo, interquartile range [IQR] 66-84; placebo, 77 mo, IQR 69-85). There was no significant difference in OS between the pazopanib and placebo arms (hazard ratio 1.0, 95% confidence interval 0.80-1.26; nominal p > 0.9). OS was worse for patients with T4 disease compared to those with less advanced disease and was better for patients with body mass index (BMI) ≥30 kg/m2 compared to those with lower BMI. OS was significantly better for patients who remained diseasefree at 2 yr after treatment compared with those who relapsed within 2 yr. These findings are consistent with the primary outcomes from PROTECT, indicating that adjuvant pazopanib does not confer a benefit in terms of OS for patients following resection of locally advanced RCC. PATIENT SUMMARY: In the randomized, double-blind, placebo-controlled phase 3 PROTECT study, overall survival was similar for patients with locally advanced renal cell carcinoma (RCC) at high risk of relapse after nephrectomy who received adjuvant therapy with pazopanib or placebo. Pazopanib is not recommended as adjuvant therapy following resection of locally advanced RCC. This trial is registered at Clinicaltrials.gov as NCT01235962.
引用
- Motzer RJ, Russo P, Haas N, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol. 2021. PMID: 33461782. doi:10.1016/j.eururo.2020.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。